Data Unavailable – Revenue and Growth Drivers
No MD&A text or income statement data was provided for CAH's 2026-Q1 10-Q filing, so revenue growth drivers cannot be identified or quantified at this time.
来源: 10-Q Item 2 – MD&A (data not available)
该报告暂无中文版，以下为英文版分析。
按公开的固定规则计算，不是模型的主观判断——但其中一项输入（高等级风险的条数）取自下方的 AI 分析。
非投资建议，也不是目标价——评的是本季基本面，不是股价。 完整方法论 →
AI核心结论
Insufficient data is available from CAH's 2026-Q1 10-Q filing to provide a meaningful one-sentence financial summary, as no financial statements or MD&A text were included in the provided data.
营收
609.4亿美元
同比 +11.05%
毛利率
4.1%
同比 +0.2 个百分点
营业利润
5.09亿美元
同比 -30.27%
SEC XBRL 原值
Cardinal Health (CAH) Q1 2026 营收 609.4亿美元，同比增长 11.0%。 营业利润率 0.8%，较去年同期的 1.3% 收窄 0.5 个百分点。
近 4 个季度：4 次超预期
| 季度 | 实际 EPS（美元） | 市场预期（美元） | 结果 |
|---|---|---|---|
| 2026年6月 | 2.60 | 2.44 | 超预期 +6.4% |
| 2026年3月 | 3.17 | 2.82 | 超预期 +12.6% |
| 2025年12月 | 2.63 | 2.40 | 超预期 +9.4% |
| 2025年9月 | 2.55 | 2.20 | 超预期 +15.9% |
由 AI 基于本次报告的 10-Q Item 2 整理
No MD&A text or income statement data was provided for CAH's 2026-Q1 10-Q filing, so revenue growth drivers cannot be identified or quantified at this time.
来源: 10-Q Item 2 – MD&A (data not available)
Without income statement or filing text data, cost pressures and margin impacts for the quarter cannot be assessed or compared to prior periods.
来源: 10-Q Item 2 – MD&A (data not available)
No forward-looking guidance or management commentary was included in the provided filing data, so outlook statements cannot be summarized.
来源: 10-Q Item 2 – MD&A (data not available)
由 AI 基于本次报告的 10-Q Item 1A 整理 · 高 2 中 2 低 0
Cardinal Health (CAH) operates in the highly regulated pharmaceutical distribution and medical products industry. Specific risk factor disclosures from the 2026-Q1 10-Q were not provided, so detailed risk descriptions cannot be extracted. This risk is generally considered high for healthcare distributors.
来源: 10-Q Item 1A – Risk Factors (data not available)
CAH has historically faced significant legal exposure related to opioid distribution litigation and settlement obligations. Without the actual filing text, the current status and financial impact of these matters cannot be confirmed for Q1 2026.
来源: 10-Q Item 1A – Risk Factors (data not available)
Cardinal Health derives a significant portion of its revenue from a small number of large customers, including major pharmacy chains. The specific concentration metrics for Q1 2026 are not available from the provided data.
来源: 10-Q Item 1A – Risk Factors (data not available)
As a pharmaceutical distributor, CAH is exposed to drug pricing changes, generic drug deflation, and supply chain disruptions. Specific disclosures on these risks for Q1 2026 are not available in the provided data.
来源: 10-Q Item 1A – Risk Factors (data not available)
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
营收 亿美元 | 609.40 亿美元 | 548.78 亿美元 | +11.05% |
营业成本 亿美元 | 584.42 亿美元 | 527.55 亿美元 | +10.78% |
毛利润 亿美元 | 24.98 亿美元 | 21.23 亿美元 | +17.66% |
营业利润 亿美元 | 5.09 亿美元 | 7.30 亿美元 | -30.27% |
净利润 亿美元 | 3.99 亿美元 | 5.06 亿美元 | -21.15% |
销售及管理费用 亿美元 | 15.42 亿美元 | 13.15 亿美元 | +17.26% |
答案基于本次 SEC 报告与本页数据